CAI
Price
$31.71
Change
-$0.64 (-1.98%)
Updated
Oct 22 closing price
Capitalization
8.96B
13 days until earnings call
Intraday BUY SELL Signals
GMAB
Price
$40.00
Change
+$0.43 (+1.09%)
Updated
Oct 22 closing price
Capitalization
24.6B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAI vs GMAB

CAI vs GMAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CAI vs. GMAB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a StrongBuy and GMAB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CAI with price predictions
Oct 22, 2026

CAI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 06, 2026

CAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 8 of 10 cases where CAI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CAI as a result. In 22 of 30 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for CAI just turned positive on October 21, 2026. Looking at past instances where CAI's MACD turned positive, the stock continued to rise in 7 of 10 cases over the following month. The odds of a continued upward trend are 70%.

Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 45 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 28 of 50 cases where CAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for CAI moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 5 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.144) is normal, around the industry mean (2.973). P/E Ratio (3.310) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (128.121) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for GMAB with price predictions
Oct 22, 2026

Aroon Indicator for GMAB shows an upward move is likely

GMAB's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator showed a similar pattern. In 144 of the 211 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

GMAB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.129) is normal, around the industry mean (2.973). P/E Ratio (31.226) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CAI vs GMAB: Fundamental Ratings
CAI
GMAB
OUTLOOK RATING
1..100
241
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4659
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
45
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAI's Valuation (86) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (93) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's Profit vs Risk Rating (100) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (100) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's SMR Rating (46) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (59) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's Price Growth Rating (35) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (37) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

CAI's P/E Growth Rating (4) in the Finance Or Rental Or Leasing industry is in the same range as GMAB (5) in the null industry. This means that CAI’s stock grew similarly to GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAIGMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
59%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
72%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
11%
Bullish Trend 1 day ago
64%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 1 day ago
64%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 15 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
62%
Aroon
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
68%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CAI: $32.35 vs. GMAB: $40.00)
Brand notoriety: CAI and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAI: 47% vs. GMAB: 145%
Market capitalization -- CAI: $8.96B vs. GMAB: $24.6B
CAI [@Biotechnology] is valued at $8.96B. GMAB’s [@Biotechnology] market capitalization is $24.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAI’s FA Score shows that 1 FA rating(s) are green while GMAB’s FA Score has 1 green FA rating(s).

  • CAI’s FA Score: 1 green, 4 red.
  • GMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, CAI is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAI’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).

  • CAI’s TA Score: 5 bullish, 3 bearish.
  • GMAB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CAI is a better buy in the short-term than GMAB.

Price Growth

CAI (@Biotechnology) experienced а +6.92% price change this week, while GMAB (@Biotechnology) price change was +5.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

CAI is expected to report earnings on Nov 04, 2026.

GMAB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CAI
Daily Signal:
Gain/Loss:
GMAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAI has been loosely correlated with BMEA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAI
1D Price
Change %
CAI100%
-1.98%
BMEA - CAI
38%
Loosely correlated
-15.23%
TWST - CAI
37%
Loosely correlated
-9.16%
RXRX - CAI
36%
Loosely correlated
-1.65%
GMAB - CAI
33%
Loosely correlated
+1.09%
ABCL - CAI
33%
Poorly correlated
-7.11%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+1.09%
AXON - GMAB
47%
Loosely correlated
+2.98%
PCVX - GMAB
42%
Loosely correlated
-0.60%
BCYC - GMAB
41%
Loosely correlated
+1.96%
RYTM - GMAB
41%
Loosely correlated
+2.57%
EXEL - GMAB
40%
Loosely correlated
+1.13%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NTWK7.750.83
+11.99%
NetSol Technologies
ETD20.791.01
+5.11%
Ethan Allen Interiors
UZX1.050.01
+0.96%
Linkage Global Inc
IOSP98.67-0.97
-0.97%
Innospec
SMMT15.55-0.28
-1.77%
Summit Therapeutics